Compare SLDP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | GERN |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | 230 | 258 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 808.3M |
| IPO Year | N/A | N/A |
| Metric | SLDP | GERN |
|---|---|---|
| Price | $2.82 | $1.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $2.17 |
| AVG Volume (30 Days) | 5.3M | ★ 11.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $48.90 | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.72 | $1.04 |
| 52 Week High | $8.86 | $2.01 |
| Indicator | SLDP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 38.45 |
| Support Level | $2.79 | $1.05 |
| Resistance Level | $3.59 | $1.30 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 11.00 | 39.58 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.